172 related articles for article (PubMed ID: 31150604)
41. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
[TBL] [Abstract][Full Text] [Related]
42. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
43. VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.
Nichele I; Zamò A; Bertolaso A; Bifari F; Tinelli M; Franchini M; Stradoni R; Aprili F; Pizzolo G; Krampera M
PLoS One; 2012; 7(12):e52811. PubMed ID: 23285191
[TBL] [Abstract][Full Text] [Related]
44. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.
Lamason RL; McCully RR; Lew SM; Pomerantz JL
Biochemistry; 2010 Sep; 49(38):8240-50. PubMed ID: 20799731
[TBL] [Abstract][Full Text] [Related]
45. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
Wobser M; Kneitz H; Bröcker EB; Becker JC
J Dtsch Dermatol Ges; 2011 Mar; 9(3):204-11. PubMed ID: 21122066
[TBL] [Abstract][Full Text] [Related]
46. Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.
Teichert M; Stumpf C; Booken N; Wobser M; Nashan D; Hallermann C; Mogler C; Müller CS; Becker JC; Moritz RK; Andrulis M; Nicolay JP; Goerdt S; Thomas M; Klemke CD; Augustin HG; Felcht M
Exp Dermatol; 2015 Jun; 24(6):424-9. PubMed ID: 25776770
[TBL] [Abstract][Full Text] [Related]
47. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma.
Dijkman R; Tensen CP; Jordanova ES; Knijnenburg J; Hoefnagel JJ; Mulder AA; Rosenberg C; Raap AK; Willemze R; Szuhai K; Vermeer MH
J Clin Oncol; 2006 Jan; 24(2):296-305. PubMed ID: 16330669
[TBL] [Abstract][Full Text] [Related]
48. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
[TBL] [Abstract][Full Text] [Related]
49. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients.
Bekkenk MW; Vermeer MH; Geerts ML; Noordijk EM; Heule F; van Voorst Vader PC; van Vloten WA; Meijer CJ; Willemze R
J Clin Oncol; 1999 Aug; 17(8):2471-8. PubMed ID: 10561311
[TBL] [Abstract][Full Text] [Related]
50. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
Frick M; Bettstetter M; Bertz S; Schwarz-Furlan S; Hartmann A; Richter T; Lenze D; Hummel M; Dreyling M; Lenz G; Gaumann A
Leuk Lymphoma; 2018 May; 59(5):1260-1263. PubMed ID: 28868954
[No Abstract] [Full Text] [Related]
51. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
[TBL] [Abstract][Full Text] [Related]
52. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
53. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
54. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
55. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
[TBL] [Abstract][Full Text] [Related]
56. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
Kim EJ; Lewis DJ; Duvic M
J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
[TBL] [Abstract][Full Text] [Related]
57. [Primary cutaneous diffuse large B-cell lymphoma, leg type: a study of clinicopathology, immunophenotype and gene rearrangement].
Wang T; Jia L; Liao W; Chen L; Chen X; Xiong Y; Hao F; Zhu X; Yang X; Wang L
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):100-5. PubMed ID: 25916640
[TBL] [Abstract][Full Text] [Related]
58. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type.
Senff NJ; Zoutman WH; Vermeer MH; Assaf C; Berti E; Cerroni L; Espinet B; de Misa Cabrera RF; Geerts ML; Kempf W; Mitchell TJ; Paulli M; Petrella T; Pimpinelli N; Santucci M; Whittaker SJ; Willemze R; Tensen CP
J Invest Dermatol; 2009 May; 129(5):1149-55. PubMed ID: 19020554
[TBL] [Abstract][Full Text] [Related]
59. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
60. High prevalence of
Schrader AMR; Jansen PM; Willemze R; Vermeer MH; Cleton-Jansen AM; Somers SF; Veelken H; van Eijk R; Kraan W; Kersten MJ; van den Brand M; Stevens WBC; de Jong D; Abdul Hamid M; Tanis BC; Posthuma EFM; Nijland M; Diepstra A; Pals ST; Cleven AHG; Vermaat JSP
Blood; 2018 May; 131(18):2086-2089. PubMed ID: 29514783
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
